S

Supernus Pharmaceuticals
D

SUPN

31.970
USD
-0.12
(-0.36%)
مغلق
حجم التداول
7,875
الربح لكل سهم
1
العائد الربحي
-
P/E
29
حجم السوق
1,789,988,247
أصول ذات صلة
ALGN
ALGN
-0.170
(-0.09%)
196.850 USD
A
ALKS
-0.200
(-0.69%)
28.790 USD
AMGN
AMGN
1.79
(0.60%)
298.52 USD
BIIB
BIIB
-1.170
(-0.88%)
132.000 USD
GILD
GILD
-0.760
(-0.68%)
110.760 USD
REGN
REGN
-0.69
(-0.13%)
546.88 USD
TEVA
TEVA
-0.045
(-0.26%)
17.010 USD
VRTX
VRTX
2.24
(0.49%)
459.27 USD
المزيد
الأخبار المقالات

العنوان: Supernus Pharmaceuticals

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.